Publication

Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.

Journal Paper/Review - Aug 28, 2022

Units
PubMed
Doi
Contact

Citation
Addeo A, Rothschild S, Holer L, Schneider M, Waibel C, Haefliger S, Mark M, Fernandez E, Mach N, Mauti L, Jermann P, Alborelli I, Calgua B, Savic-Prince S, Joerger M, Früh M. Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. Lung Cancer 2022; 172:154-159.
Type
Journal Paper/Review (English)
Journal
Lung Cancer 2022; 172
Publication Date
Aug 28, 2022
Issn Electronic
1872-8332
Pages
154-159
Brief description/objective

Patients with advanced squamous-cell lung cancer (SQCLC) frequently (46%) exhibit tumor overexpression of fibroblast growth factor receptor (FGFR) messenger ribonucleic acid (mRNA). Rogaratinib is a novel oral pan-FGFR inhibitor with a good safety profile and anti-tumor activity in early clinical trials as a single agent in FGFR pathway-addicted tumors. SAKK 19/18 determined clinical activity of rogaratinib in patients with advanced SQCLC overexpressing FGFR1-3 mRNA.